相关实验视频

Updated: Sep 11, 2025

Modeling Chemotherapy Resistant Leukemia In Vitro

Modeling Chemotherapy Resistant Leukemia In Vitro

Published on: February 9, 2016

白血病负担影响了小儿B细胞急性淋巴细胞白血病中布利纳图莫马布的有效性和毒性

Weiling Yan¹, Shaoyan Hu², Wenjin Gao³

¹Department of Hematology & Oncology, Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou, Zhejiang, China.

Cancer medicine

|August 19, 2025

概括

布利纳图莫马布有效治疗儿科B细胞急性淋巴细胞白血病 (B-ALL). 较低的初始白血病负担与更好的结果和较少的不良事件 (AE) 在现实世界B-ALL治疗中相关.

科学领域:

血液学血液学血液学
儿科瘤学儿科瘤学
免疫治疗是一种免疫疗法.

背景情况:

布利纳图莫马布已获批准用于治疗儿科B细胞急性淋巴细胞白血病 (B-ALL).
现实世界的数据对于了解不同患者群体的治疗疗效至关重要.

研究的目的:

调查初始白血病负担与小儿B-ALL中的布利纳图莫马布疗效之间的关联.
评估现实世界的结果,包括缓解率,生存率和不良事件.

主要方法:

一项现实研究包括304名儿童患者 (0-18岁) 患有CD19阳性B-ALL,接受了blinatumomab治疗.
在2021年1月至2023年5月期间,从中国的14个中心收集了数据.
患者根据治疗前的爆炸百分比和MRD状态进行了分层.

主要成果:

75.9%的患有>5%爆发的患者实现了完全缓解 (CR),69.0%的患者实现了MRD阴性.
98.9%的MRD阳性患者实现了MRD阴性.
与非完全缓解 (NCR) 组相比,患白血病负担较低的患者 (MRD或MRD+) 的30个月整体存活率 (OS) 和无事件存活率 (EFS) 显著改善.
3级以上的不良事件 (AE) 在41.4%的患者中发生,血液毒性是最常见的;严重的细胞因子释放综合征 (CRS) 和神经毒性很少发生.

结论:

布利纳莫马布在实际的儿科B-ALL治疗中显示出有效性和良好的安全性.
较低的初始白血病负担与改善的生存结果和不良事件发生率的减少有关.

关键词:

急性淋巴细胞白血病急性淋巴细胞白血病这就是Blinatumomabomab.儿科儿科儿科现实世界的研究研究.

更多相关视频

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

相关概念视频

Bone Marrow Sampling and Transplants

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...

Disorders of Leukocytes

Disorders of Leukocytes

Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...